Delving into the Latest Updates on Fat Emulsion(C14-24) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Fat Emulsion(C14-24), 大豆油/卵磷脂, 脂肪乳(C14-24)

+ [2]

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

esssential fatty acid deficiency

Inactive Indication-

Originator Organization

Fresenius Kabi Deutschland GmbH

Active Organization

Fresenius Kabi Deutschland GmbH

Fresenius Kabi SSPC Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (07 Oct 1975),

esssential fatty acid deficiency

Regulation-

Login to view timeline

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Start Date15 Sep 2024

Sponsor / Collaborator

Mayo Clinic

CTRI/2023/11/060068

/ CompletedPhase 4

Effect of Post-conditioning with Intralipid in Patients Undergoing Off - Pump Coronary Artery Bypass Surgery - NIL

Start Date30 Dec 2023

Sponsor / Collaborator-

CTRI/2023/11/059964

/ Not yet recruitingPhase 3IIT

CARDIOPROTECTIVE EFFECT OF INTRALIPID IN OFF PUMP CORONARY ARTERY BY PASS SURGERY ; PROSPECTIVE RANDOMIZED CONTROL STUDY IN DEPARTMENT OF ANAESTHESIA , SMS MEDICAL COLLEGE JAIPUR - nil

Start Date23 Nov 2023

Sponsor / Collaborator-

100 Clinical Results associated with Fat Emulsion(C14-24)

Login to view more data

100 Translational Medicine associated with Fat Emulsion(C14-24)

Login to view more data

100 Patents (Medical) associated with Fat Emulsion(C14-24)

Login to view more data

2,526

Literatures (Medical) associated with Fat Emulsion(C14-24)

01 Apr 2025·Water Research

Micro-nano bubble ozonation for effective treatment of ibuprofen-laden wastewater and enhanced anaerobic digestion performance

Article

Author: Sun, Lianpeng ; Lu, Hui ; Qiao, Lei ; Jia, Yanyan ; Zhou, Sining ; Khanal, Samir Kumar

The pharmaceutical industry plays a crucial role in driving global economic growth but also poses substantial environmental challenges, particularly in the efficient treatment of production wastewater. This study investigates the efficacy of micro-nano bubble (MNB) ozonation for treating high-strength ibuprofen (IBU)-laden wastewater (49.9 ± 2.3 mg/L) and mitigating its inhibitory effects on the anaerobic digestion (AD) of intralipid (IL)-laden wastewater. Our findings demonstrated that MNB ozonation achieved a 99.0 % removal efficiency of IBU within 70 min, significantly surpassing the 69.8 % efficiency observed with conventional ozonation under optimal conditions. Both conventional and MNB ozonation primarily transformed IBU through oxidation processes, including hydroxylation and the conversion of CH bonds to C = O groups, along with carbon cleavage. However, MNB ozonation markedly reduced the toxicity of IBU-laden wastewater by further transforming toxic by-products, particularly under mildly alkaline conditions (pH 7.2 and 9.0). This reduction in toxicity led to a significant improvement in subsequent AD performance; specifically, a 70-min MNB ozonation pretreatment enhanced methane production by 48.1 %, increased chemical oxygen demand removal by 35.6 %, and reduced fatty acid accumulation compared to the control without pretreatment. Additionally, the effluent from MNB ozonation positively impacted the microbial community, particularly by enriching syntrophic bacteria and methanogens. Overall, these findings offered new insights into the behavior and toxicity of IBU oxidation by-products in both conventional and MNB ozonation processes. Furthermore, this study proposed a novel strategy for the combined treatment of IBU- and IL-laden wastewaters, establishing a robust foundation for advancing MNB ozonation technology in engineered pharmaceutical wastewater treatment.

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Investigation on concentration detection of turbid solution based on hemisphere sample cell and multidimensional spectroscopy

Article

Author: Ji, Wenlong ; Zheng, Huayan ; Xu, Yun ; Zhang, Jianxin

The study developed a hemisphere sample cell and constructed a multidimensional spectroscopy acquisition system to enhance the accuracy of detecting turbid solution with scattering properties. The system simultaneously captures absorption and scattering information from the tested samples. Monte Carlo simulation was employed to model the transmission light intensity distribution data from sample cells of various shapes. It was found that the hemisphere sample cell increases the dimensionality of transmission light intensity information and enables the acquisition of more scattering-related data. Furthermore, 46 samples of intralipid-20% solution with varying concentrations were examined. Models were constructed using partial least squares (PLS) regression with one-dimensional and two-dimensional light intensity distribution data. The results indicate that the model using two-dimensional light intensity distribution data significantly outperforms the model using one-dimensional data, reducing the root mean square error by 39.96% and increasing the correlation coefficient by 0.332%. Experimental results demonstrate that the multidimensional spectroscopic modeling method employing the hemisphere sample cell can significantly enhance the accuracy and speed of detecting chemical composition concentrations in turbid solution.

18 Dec 2024·The Journal of Clinical Endocrinology & Metabolism

Beta2-agonist Impairs Muscle Insulin Sensitivity in Persons With Insulin Resistance

Article

Author: Havelund, Jesper ; Thomassen, Martin ; Bangsbo, Jens ; Færgeman, Nils ; Hostrup, Morten ; Onslev, Johan ; Fiorenza, Matteo ; Wojtaszewski, Jørgen F P

AbstractContextGiven the promising effects of prolonged treatment with beta2-agonist on insulin sensitivity in animals and nondiabetic individuals, the beta2-adrenergic receptor has been proposed as a target to counter peripheral insulin resistance. On the other hand, rodent studies also reveal that beta2-agonists acutely impair insulin action, posing a potential caveat for their use in treating insulin resistance.ObjectiveTo assess the impact of beta2-agonist on muscle insulin action and glucose metabolism and identify the underlying mechanism(s) in 10 insulin-resistant subjects.Methods and participantsIn a crossover design, we assessed the effect of beta2-agonist on insulin-stimulated muscle glucose uptake during a 3-hour hyperinsulinemic isoglycemic clamp with and without intralipid infusion in 10 insulin-resistant, overweight subjects. Two hours into the clamp, we infused beta2-agonist. We collected muscle biopsies before, 2 hours into, and by the end of the clamp and analyzed them using metabolomic and lipidomic techniques.ResultsWe establish that beta2-agonist, independently from and additively to intralipid, impairs insulin-stimulated muscle glucose uptake via different mechanisms. In combination, beta2-agonist and intralipid nearly eliminates insulin-dependent muscle glucose uptake. Although both beta2-agonist and intralipid elevated muscle glucose-6-phosphate, only intralipid caused accumulation of downstream muscle glycolytic intermediates, whereas beta2-agonist attenuated incorporation of glucose into glycogen.ConclusionOur findings suggest that beta2-agonist inhibits glycogenesis, whereas intralipid inhibits glycolysis in skeletal muscle of insulin-resistant individuals. These results should be addressed in future treatment of insulin resistance with beta2-agonist.

100 Deals associated with Fat Emulsion(C14-24)

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
esssential fatty acid deficiency	US	Fresenius Kabi Deutschland GmbH	07 Oct 1975

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2024	Not Applicable	-	-	Intralipid	jvmwvbdrey(pbojmirhhm) = xlywagkmpr muelxbtpxe (jvnidminaw ) View more	-	14 Jun 2024
				Saline	jvmwvbdrey(pbojmirhhm) = ecygxunyhj muelxbtpxe (jvnidminaw ) View more
NCT00672854 (TPN2, CTgov)	Phase 2/3	Dietary Supplement \| stress oxidative	100	Intralipid (Total Parenteral Nutrition (TPN) Given Intralipid 20%)	mnsbdkppjb(nftezjghqi) = czbazglpsa xlflcpiycz (mqnvqdfwlq, eadtujzxkk - pxpwwcqhjn) View more	-	01 Aug 2014
				ClinOleic (Total Parenteral Nutrition (TPN) Given ClinOleic 20%)	mnsbdkppjb(nftezjghqi) = hpahmxfkqx xlflcpiycz (mqnvqdfwlq, bhthvjbihv - qdntqgjfpx) View more
NCT01096771 (CTgov)	Phase 2	Respiratory Distress Syndrome, Acute	14	ClinOleic (Experimental ClinOleic 20%)	hwlmdoyfrw(vznkjppkmz) = hbtyxkstji kqyoofssrd (gnkillcefx, sveznesxxj - abbbvoiqsk) View more	-	26 May 2014
				Intralipid (Control: Intralipid 20%)	hwlmdoyfrw(vznkjppkmz) = jffumcptgs kqyoofssrd (gnkillcefx, ejvclpempl - fflbjshndj) View more